← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $623B	3,892	+79	+2%	$278B
2	2 AbbVie ABBV $510B	3,506	+134	+4%	$250B
3	3 Merck MRK $372B	3,498	-55	-2%	$222B
4	4 Pfizer PFE $169B	2,917	+36	+1%	$109B
5	5 Amgen AMGN $238B	2,830	+39	+1%	$133B
6	6 Bristol-Myers Squibb BMY $125B	2,266	+111	+5%	$80B
7	7 Gilead Sciences GILD $197B	1,721	+40	+2%	$87.4B
8	8 Regeneron Pharmaceuticals REGN $83B	1,392	+57	+4%	$97.5B
9	9 Novartis NVS $287B	1,313	+5	+0.4%	$15.2B
10	10 AstraZeneca AZN $261B	1,231	+18	+1%	$39.1B
11	11 GSK GSK $99.3B	901	+15	+2%	$12.7B
12	12 DELISTED Exact Sciences EXAS	600	+55	+10%	$12.4B
13	13 Incyte INCY $23.1B	592	+7	+1%	$12B
14	14 Halozyme HALO $13.7B	508	+48	+10%	$7.17B
15	15 Lantheus LNTH $6.53B	499	+47	+10%	$7.71B
16	16 Natera NTRA $57.8B	495	+20	+4%	$15.4B
17	17 Jazz Pharmaceuticals JAZZ $14.1B	478	+21	+5%	$6.43B
18	18 Exelixis EXEL $15.3B	453	+38	+9%	$6.45B
19	19 Qiagen QGEN $9.55B	331	+25	+8%	$7.05B
20	20 DELISTED Blueprint Medicines BPMC	319	+14	+5%	$6.04B
21	21 Takeda Pharmaceutical TAK $63.3B	300	+15	+5%	$1.02B
22	22 BioNTech BNTX $22.7B	296	+10	+3%	$5.24B
23	23 Veracyte VCYT $3.61B	292	+52	+22%	$2.78B
24	24 Iovance Biotherapeutics IOVA $6.55B	286	-9	-3%	$2.21B
25	25 Guardant Health GH $22.2B	271	-11	-4%	$2.86B